on MEDINCELL (EPA:MEDCL)
H.C. Wainwright & Co. Initiates MedinCell’s Coverage with "Buy" Recommendation
MedinCell, a biopharmaceutical company, announced that H.C. Wainwright & Co. has initiated coverage with a "Buy" rating and a price target of €24. This represents an 80% potential increase from the previous day's stock price at market close.
Christophe Douat, CEO of MedinCell, emphasized the significance of this coverage. He stated it underscores the growing interest in MedinCell within the U.S. biopharmaceutical sector and strengthens their objective to enhance visibility among American investors.
This initiation follows significant milestones for MedinCell. These include U.S. FDA approval of UZEDY® and positive Phase 3 results for mdc-TJK. Additionally, a collaboration with AbbVie to co-develop and commercialize multiple therapeutic products was announced.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all MEDINCELL news